DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Esperion Therapeutics, Inc. & Encourages ...
06 July 2018 - 6:35AM
Business Wire
The Schall Law Firm, a national shareholder rights litigation
firm, announces that it is investigating claims on behalf of
investors of Esperion Therapeutics, Inc. ("Esperion" or the
"Company") (NASDAQ: ESPR) for violations of §§10(b) and 20(a) of
the Securities Exchange Act of 1934 and Rule 10b-5 promulgated
thereunder by the U.S. Securities and Exchange Commission.
The investigation focuses on whether the Company issued false
and/or misleading statements and/or failed to disclose information
pertinent to investors. Esperion failed to disclose that Bempedoic
acid, the company’s cholesterol-lowering medication, had serious
safety risks up to and including death. As a result of the failure
to disclose this information, Esperion Therapeutics’ financial
statements, claims about the company’s business operations, and
financial prospects were materially false and misleading throughout
the class period. According to the lawsuit, when accurate
information about Esperion Therapeutics became apparent in the
market, investors suffered damages.
If you are a shareholder who suffered a loss, click here to
participate.
We also encourage you to contact Brian Schall, or Sherin
Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite
404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights
free of charge. You can also reach us through the firm's website
at www.schallfirm.com, or by email
at brian@schallfirm.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder
rights litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and rules of
ethics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180705005594/en/
The Schall Law FirmBrian Schall, Esq.Sherin Mahdavian,
Esq.310-301-3335info@schallfirm.comwww.schallfirm.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2024 to May 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2023 to May 2024